HC Wainwright & Co. analyst Edward White downgrades Vyant Bio (NASDAQ:VYNT) from Buy to Neutral.
P/E Ratio Insights for CME Gr
In the current session, the stock is trading at $199.75, after a 0.55% spike. Over the past month,…
HC Wainwright & Co. Downgrades Vyant Bio to Neutral
HC Wainwright & Co. analyst Edward White downgrades Vyant Bio (NASDAQ:VYNT) from Buy to Neutral.
Related Posts
Here’s How Much $1000 Invested In Booking Holdings 20 Years Ago Would Be Worth Today
Booking Holdings (NASDAQ:BKNG) has outperformed the market over the past 20 years by 20.1% on an annualized basis…
Evolent Health Q4 Adj. EPS $0.10 Misses $0.16 Estimate, Sales $382.43M Beat $372.93M Estimate
Evolent Health (NYSE:EVH) reported quarterly earnings of $0.10 per share which missed the analyst consensus estimate of $0.16 by 37.5 percent. This is a 25 percent increase over earnings of $0.08 per share from the same
3D Systems Receives FDA Clearance For NextDent Base
Third-generation material for printing removable dentures offers high break resistance, accurate printing, and repeatable results Material part of company's portfolio of 30 unique NextDent resins – the largest